MDACC Study No:2013-0302 ( NCT No: NCT01829711)
Title:A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Moxetumomab
Study Status:Closed
Study Description:Why is this study being done?
Moxetumomab pasudotox is an investigational agent that was developed to target
a particular molecule, CD22, that can be found on the surface of cancer cells
and to selectively kill the cells that have the molecule. Moxetumomab
pasudotox has not been approved by the Food and Drug Administration (FDA).
Overall about 155 patients, both children and adults, have been treated with
moxetumomab pasudotox with limited side effects which are discussed in the
risks section of the consent.

We hope this study will show that moxetumomab pasudotox can work in humans to
kill cancer cells especially those cells that have CD22 on their surface.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase III
Treatment Agents:Moxetumomab
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:MedImmune
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-745-0394
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults